Predicting Length-of-Stay & Risk of Mortality for ICU Patients

Pangaea Data Awarded Top Tier Co-Sell Partnership Status by Microsoft

Pangaea Named ‘Digital Solution of the Year’ by UK Government’s Department for International Trade

Global Pharmaceutical Proves Pangaea’s AI

Go back

Pangaea is Selected for AstraZeneca Japan’s i2.JP

We have been selected to be part of i2.JP, an open initiative by AstraZeneca Japan.

We are continuing to expand our network of healthcare and pharmaceutical partners. Earlier this year, we were selected for Innovation Infusion Japan (i2.JP), an open initiative by AstraZeneca Japan that aims to connect healthcare professionals, local governments, academia and private companies. The i2.JP initiative draws members from all over the world to jointly work on collective and practical solutions for important issues in healthcare. Participants in the initiative focus on creating solutions and services for patients and healthcare professionals that focus on diagnosis, devices, digital, drugs, and experience design.

“We are pleased that Pangaea has joined the i2.JP network,” Liu Lei, Ph.D., Innovation Partnerships & i2.JP Director, said in a statement. “Their expertise in extracting insights from unstructured clinical text is an invaluable asset to our efforts to jointly work out optimal solutions for important challenges in the healthcare field. We look forward to working with them and our other partners.”

See More Here